ANXA5 and cholangiocarcinoma: Previous studies have demonstrated that inhibition of ANXA5 reduced the proliferation of murine hepatocarcinoma Hca-P cells with about a 25% lymph node metastasis rate (28, 29), human cholangiocarcinoma cells (30), and pre-osteoblastic cells (31).